Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS

Conclusions
In patients with PPMS, long-term treatment with fingolimod 0.5 mg/d for up to 5 years led to an expected decrease of approximately 70% in mean ALC and did not appear to correlate with increased risk of infection.

Classification of evidence
Because this is a secondary analysis, this study provides Class II evidence that long-term PPMS treatment with fingolimod decreased mean ALC by approximately 70%, but did not significantly increase infection risk.

Source: Neurology Neuroimmunology and Neuroinflammation - September 10, 2019 Category: Neurology Authors: Fox, E. J., Lublin, F. D., Wolinsky, J. S., Cohen, J. A., Williams, I. M., Meng, X., Ziehn, M., Kolodny, S., Cree, B. A. C. Tags: All Infections, Clinical trials Randomized controlled (CONSORT agreement), Multiple sclerosis Article Source Type: research